In the News

Will there still be a role for ribavirin and pegylated interferon-alfa?

by Traci Bratton

May 27, 2015
Print
Email

MedPage Today invited specialists from leading medical institutions to weigh in on the latest advancements in hepatitis C with one question each day for 10 days. Hear what E. Turner Overton, MD, associate professor of medicine, University of Alabama at Birmingham, had to say.

http://www.medpagetoday.com/HOTTOPICSHCV/InfectiousDisease/Hepatitis-Videos/1125

back to top

Media Policy Guidelines

Marketing and Communications

UAB Home

The University of Alabama at Birmingham

1720 2nd Ave South

Birmingham, AL 35294

Public Relations: (205) 934-3884

Media Specialist On Call: (205) 934-3411

Contact UAB
|
|
A-Z Site Index
|
Privacy
|
Terms of Use
|

UAB is an Equal Employment/Equal Educational Opportunity Institution dedicated to providing equal opportunities and equal access to all individuals regardless of race, color, religion, ethnic or national origin, sex (including pregnancy), genetic information, age, disability, religion, sexual orientation, gender identity, gender expression, and veteran’s status. As required by Title IX, UAB prohibits sex discrimination in any education program or activity that it operates. Individuals may report concerns or questions to UAB’s Assistant Vice President and Senior Title IX Coordinator. The Title IX notice of nondiscrimination is located at uab.edu/titleix.